Increasing legislative focus on pharmaceutical monopoly power and price transparency poses a bearish headwind.

Mentioned only as a potential suitor for Abivax (ABVX), indicating broad interest from large pharma in Abivax's assets.

The company faces significant political and regulatory risk due to government-mandated price caps on insulin. This pressure has led to price slashing, which can curtail long-term profitability and is a key risk factor for investors.